Skip to content

LinXis Biopharmaceuticals (Netherlands)

Request correction

A biopharmaceutical company pioneering Fibrobodies® and Fibrobody®-Drug Conjugates for targeted drug delivery to treat fibrotic diseases.

Last updated September 1, 2026

AI crawler reads

2requests

1companies
  • Anthropic2
Profile
2
Controversies
0
JSON · MD
0
First read
Nov 4, 2026
Latest read
Nov 4, 2026

From this site's server log

Overview

LinXis Biopharmaceuticals is a company based in Amsterdam, Netherlands. It is the first to develop Fibrobodies® and Fibrobody®-Drug Conjugates to diagnose and combat liver fibrosis and other fibrotic diseases. The company's mission is to have a turnkey solution for bringing drugs to targeted cells.

History

LinXis Biopharmaceuticals is a company in Amsterdam, Netherlands. It is the first to develop Fibrobodies® and Fibrobody®-Drug Conjugates to diagnose and combat liver fibrosis and other fibrotic diseases. The company's mission is to have a turnkey solution for bringing drugs to targeted cells. In 2024, Guus van Dongen joined LinXis as Chief Scientific Officer. In 2025, LinXis received a TKI-PPP grant for the FibroTarget project, published a key paper on its lead Fibrobody® in EJNMMI, and joined the PHAEDRA-IMPACT consortium as an industrial partner.

  • Guus van Dongen joins LinXis as Chief Scientific Officer

    [4]
  • LinXis receives TKI-PPP grant

    [4]
  • LinXis publishes key paper on lead Fibrobody® in EJNMMI

    [4]
  • LinXis joins PHAEDRA-IMPACT consortium

    [4]

Products and positioning

  • Fibrobodies®

    Pan-fibrosis drug delivery vectors, small, smart, and selective, suitable for diagnosis and treatment, selective for activated myofibroblasts.

  • Fibrobody®-Drug Conjugates

    How we deliver medicine to specific cells.

  • Fibrobody®-Tracer Conjugates

    How we target specific cells.

Sources5 sources

Cite this profile: Cite the canonical profile. /brand-wiki/linxis-biopharmaceuticals-netherlands · Editorial policy · How profiles are compiled